Molecular weight
Cagrilintide ~3949 Da + Semaglutide ~4113.6 Da
REDEFINE 1 trial: ~22.7% mean body weight loss at 68 weeks, exceeding semaglutide alone (~16.2%). ~50% of participants achieved ≥25% weight reduction. NDA filed Dec 2025; FDA decision expected Q4 2026.
Dual-agonist combination: Cagrilintide activates amylin receptors for satiety/gastric slowing. Semaglutide activates GLP-1R for insulin secretion and appetite suppression. Complementary satiety pathways for synergistic weight loss.
~22.7% weight loss (REDEFINE 1); superior to semaglutide alone; NDA filed Dec 2025; dual amylin+GLP-1 mechanism.
Research data is not a treatment plan. If you are considering CagriSema, the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.
Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.Interactive tools for this compound:
Reconstitution calculator · Full deep dive · Peptide fundamentals